In the competitive diabetes treatment market, there is a growing focus on developing next-generation therapies that not only provide cardiovascular and renal protection like existing SGLT-2 inhibitors but also manage postprandial blood sugar levels. In this context, Jeil Pharmaceutical has garnered attention by revealing the Phase 2 clinical trial results for its oral type 2 diabetes drug candidate, JP-2266.
On July 30, Jeil Pharmaceutical announced that the results of the Phase 2 study for JP-2266 were published in the international journal, Diabetes & Metabolism Journal (DMJ).
JP-2266 is a dual inhibitor that targets both SGLT-2, which inhibits glucose reabsorption in the kidneys, and SGLT-1, which delays glucose absorption in the intestines. It is being developed as a next-generation diabetes treatment that combines the benefits of existing SGLT-2 inhibitors with postprandial blood sugar control.
The clinical trial involved 156 patients with type 2 diabetes whose blood sugar levels were not adequately controlled by diet and exercise alone. Conducted across 28 medical institutions in South Korea, the study employed a randomized, double-blind, placebo-controlled design, with Professor Cha Bong-soo from Severance Hospital's Endocrinology Department serving as the trial coordinator.
According to the study results, after 12 weeks of treatment, JP-2266 significantly reduced hemoglobin A1c (HbA1c) levels compared to the placebo group. The estimated treatment difference (ETD) was a decrease of 0.94 percentage points in the 5 mg group and 0.97 percentage points in the 10 mg group, both achieving statistical significance.
The proportion of patients reaching an HbA1c level of less than 7% was 70.6% in the 10 mg group and 66.7% in the 5 mg group. Improvements were also observed in fasting blood sugar and blood sugar levels one and two hours after meals, with a reduction of approximately 63 to 68 mg/dL in postprandial blood sugar at the 12-week mark.
Weight loss and improvements in certain cardiovascular and metabolic risk factors were also noted. Notably, the 10 mg group experienced a reduction in systolic blood pressure, along with improvements in insulin resistance and beta-cell function indicators. Safety assessments indicated that both doses had a similar incidence of adverse events compared to the placebo group, confirming overall good tolerability.
Professor Cha stated, "In Asian countries where carbohydrate intake is high, managing postprandial blood sugar is crucial, making JP-2266 a potentially significant treatment option. Further confirmation of its efficacy and safety is needed in Phase 3 trials."
Meanwhile, Jeil Pharmaceutical is accelerating the development of new drugs following the success of its potassium-competitive acid blocker (P-CAB) reflux disease treatment, Zagut. The company aims to shift its focus from introducing products to a research and development (R&D) centered approach, emphasizing its pipeline of diabetes treatments and anticancer drugs.
On July 30, Jeil Pharmaceutical announced that the results of the Phase 2 study for JP-2266 were published in the international journal, Diabetes & Metabolism Journal (DMJ).
JP-2266 is a dual inhibitor that targets both SGLT-2, which inhibits glucose reabsorption in the kidneys, and SGLT-1, which delays glucose absorption in the intestines. It is being developed as a next-generation diabetes treatment that combines the benefits of existing SGLT-2 inhibitors with postprandial blood sugar control.
The clinical trial involved 156 patients with type 2 diabetes whose blood sugar levels were not adequately controlled by diet and exercise alone. Conducted across 28 medical institutions in South Korea, the study employed a randomized, double-blind, placebo-controlled design, with Professor Cha Bong-soo from Severance Hospital's Endocrinology Department serving as the trial coordinator.
According to the study results, after 12 weeks of treatment, JP-2266 significantly reduced hemoglobin A1c (HbA1c) levels compared to the placebo group. The estimated treatment difference (ETD) was a decrease of 0.94 percentage points in the 5 mg group and 0.97 percentage points in the 10 mg group, both achieving statistical significance.
The proportion of patients reaching an HbA1c level of less than 7% was 70.6% in the 10 mg group and 66.7% in the 5 mg group. Improvements were also observed in fasting blood sugar and blood sugar levels one and two hours after meals, with a reduction of approximately 63 to 68 mg/dL in postprandial blood sugar at the 12-week mark.
Weight loss and improvements in certain cardiovascular and metabolic risk factors were also noted. Notably, the 10 mg group experienced a reduction in systolic blood pressure, along with improvements in insulin resistance and beta-cell function indicators. Safety assessments indicated that both doses had a similar incidence of adverse events compared to the placebo group, confirming overall good tolerability.
Professor Cha stated, "In Asian countries where carbohydrate intake is high, managing postprandial blood sugar is crucial, making JP-2266 a potentially significant treatment option. Further confirmation of its efficacy and safety is needed in Phase 3 trials."
Meanwhile, Jeil Pharmaceutical is accelerating the development of new drugs following the success of its potassium-competitive acid blocker (P-CAB) reflux disease treatment, Zagut. The company aims to shift its focus from introducing products to a research and development (R&D) centered approach, emphasizing its pipeline of diabetes treatments and anticancer drugs.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.